https://www.selleckchem.com/pr....oducts/ac-fltd-cmk.h
46-33.74; alirocumab 34.07months, 95% CI 33.92-34.22]. These results, along with those of the control groups, were analyzed and interpreted narratively. Univariate statistics were conducted, but no network meta-analysis was performed. The experience presented herein indicates that a framework of evidence assessment focused on the RMST is a worthwhile option. Our study is in line with the growing literature that has recently emphasized the methodological advantages of the RMST. The experience presented herein indicates that a framewo
Like
Comment
Share
